Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | EML4 - ALK ALK L1152R |
| Therapy | Ceritinib |
| Indication/Tumor Type | lung cancer |
| Response Type | resistant |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| EML4 - ALK ALK L1152R | lung cancer | resistant | Ceritinib | Preclinical - Cell culture | Actionable | In a preclinical study, lung cancer cells expressing ALK L1152R in the context of EML4-ALK demonstrated resistance to Zykadia (ceritinib) treatment in culture (PMID: 31925410). | 31925410 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (31925410) | Defining the landscape of ATP-competitive inhibitor resistance residues in protein kinases. | Full reference... |